KPC Pharmaceuticals
Research and development, production, and marketing of botanical drugs.
Launch date
Employees
Market cap
CAD1.7b
Enterprise valuation
CAD1.5b (Public information from Sep 2024)
Share price
CNY12.2 600422.SS
Kunming Yunnan (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.7b | 8.3b | 8.3b | 7.7b | 8.5b | 9.8b | 10.8b |
| % growth | (5 %) | 7 % | - | (7 %) | 10 % | 15 % | 10 % |
| EBITDA | 704m | 902m | 823m | 906m | 930m | 1.1b | 1.3b |
| % EBITDA margin | 9 % | 11 % | 10 % | 12 % | 11 % | 12 % | 12 % |
| Profit | 457m | 508m | 383m | 445m | 583m | 757m | 912m |
| % profit margin | 6 % | 6 % | 5 % | 6 % | 7 % | 8 % | 8 % |
| EV / revenue | 0.8x | 1.0x | 1.3x | 2.0x | 1.3x | 1.1x | 1.0x |
| EV / EBITDA | 9.3x | 9.3x | 13.0x | 17.5x | 11.7x | 9.5x | 8.1x |
| R&D budget | 128m | 101m | 69.7m | 71.3m | - | - | - |
| R&D % of revenue | 2 % | 1 % | 1 % | 1 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about KPC Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
